AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02998632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mineralized plasmatic matrix for bone augmentation
Description: Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
Study NCT02998632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone for bone augmentation
Description: Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
Study NCT01765309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral mastectomy with reconstruction
Description: In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
Study NCT02113254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corn zeaxanthin
Description: The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
Study NCT04705493 — intervention group
Intervention type: OTHER
Intervention: fluid resuscitation with crystalloid
Description: give two-volume of fluids initial 250ml then another 250 ml
Study NCT00586092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bevacizumab, ABT-510
Description: * Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID\*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days\*~* Stage 2 (RPTD) ABT-510: X mg SC BID\*\*, bevacizumab: Y mg/kg IV every 14 days\*\*~  * Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~    * \*Both agents begin on Day 1 of Cycle 1.~      * \*\*At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination.
Study NCT00992589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium 5 mg
Description: Rabeprazole Sodium 5 mg capsules once daily in the morning.
Study NCT00992589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium 10 mg
Description: Rabeprazole Sodium 10 mg capsules once daily in the morning.
Study NCT00992589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules once daily in the morning.
Study NCT00915499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VPAP Adapt SV
Description: Comparison of ASV and CPAP modes
Study NCT03360864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Description: Patient will participate to a education program.
Study NCT02074891 — intervention group
Intervention type: DRUG
Intervention: coformulated TDF/FTC
Description: Daily oral dose of coformulated TDF/FTC
Study NCT01542424 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Prescribed at the discretion of the physician
Study NCT01542424 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed at the discretion of the physician
Study NCT00965965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New colorectal cancer screening patient education document
Description: The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
Study NCT00965965 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional colorectal cancer screening education document
Description: The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
Study NCT00329849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY-CRM conjugate vaccine
Description: MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
Study NCT00329849 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ACWY-PS polysaccharide vaccine
Description: MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
Study NCT00435045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin
Description: Lovaza + atorvastatin
Study NCT00435045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin + placebo
Study NCT01141062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips MR-guided HIFU
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
Study NCT03469778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Therapy
Description: Robotic Therapy
Study NCT04311593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CD4, CD19, CD38, CD56 and CD11b
Description: measuring CD markers by flowcytometry
Study NCT02361645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% eyedrops
Study NCT02361645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5% eyedrops
Study NCT02361645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09% eyedrops
Study NCT02361645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1% eyedrops
Study NCT01001702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
Study NCT00988247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).
Study NCT00988247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Aerosol
Description: Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
Study NCT02243228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Study NCT02633371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin 3% gel
Study NCT01255774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: An open-label, study of intravitreally administered ranibizumab
Study NCT02557178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coaching
Description: Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
Study NCT00434967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: 32 mg oral tablet
Study NCT00434967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: 32 mg oral tablet
Study NCT00434967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 25 mg oral tablet
Study NCT00434967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 25 mg oral tablet
Study NCT00434967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan/HCT 32/25 mg
Study NCT00976144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
Study NCT01989221 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sancuso®
Description: Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
Study NCT04111614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib tablet
Description: Single dose of tofacitinib 5 mg tablet
Study NCT04111614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib Oral Solution
Description: Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
Study NCT00670826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vitalHEAT vH2 Temperature Management System
Description: The vH2 system utilizes a combination of localized heat and vacuum application to one hand \& forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
Study NCT00670826 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arizant Healthcare Bair Hugger Temperature Management System
Description: The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
Study NCT00462787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00462787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Study NCT00462787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00462787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study NCT03743077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training including inspiratory muscle training
Description: Volunteers will participate in the the spinal mobility fitness training program for a frequency of one to 3 times a week with pre and post tests including four objective measures of function (timed t-shirt test, timed transfer test, four direction reach test and trunk test of strength) and a pre and post subjective interview. In addition to the program consenting volunteers will perform inspiratory muscle training as a home program and submit weekly diaries tracking their training. The inspiratory muscle trainer by Respironics provides specific pressure for inspiratory muscle strength and endurance, regardless of how quickly or slowly patients breathe. It exercises respiratory muscles and improves breathing. It Improves muscle strength and is easy to use.
Study NCT04355585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: 1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
Study NCT04355585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
Study NCT00462787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00462787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study NCT01552798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: 2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
Study NCT01552798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
Study NCT01552798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
Study NCT01791959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: synbiotic
Description: 2 symbiotics capsules per day for 28 weeks
Study NCT01791959 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 Maltodexterin capsules as a placebo per day for 28 weeks
Study NCT01097928 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter directed debulking of Pulmonary Embolus
Description: A catheter will be used to break up the pulmonary embolism
Study NCT03457961 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
Study NCT03377920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-check Dial device (Clement Clarke International Ltd, Harlow, UK)
Description: * pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~* 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's
Study NCT03261115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No topical anesthesia
Description: Lack of use of topical anesthesia application prior to infiltration injection intra-orally
Study NCT02922387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
Study NCT02922387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral support
Description: An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
Study NCT02922387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
Study NCT01586988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMAGE Intervention
Description: Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
Study NCT04141657 — intervention group
Intervention type: OTHER
Intervention: Pharmacogenetic test
Description: Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.
Study NCT02316509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0927
Description: GDC-0927 will be administered as per schedule specified in the respective arm.
Study NCT01088607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (UDCA)
Description: Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
Study NCT02085031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal Roux-en-Y esophagojejunostomy
Description: During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
Study NCT02085031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Roux-en-Y esophagojejunostomy
Description: During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
Study NCT04121078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 capsule.
Study NCT04121078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin infusion.
Study NCT03483129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation
Description: 15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
Study NCT02480946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320
Description: As described in the arm descriptions
Study NCT02480946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As described in the arm descriptions
Study NCT02480946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Background therapy as described in the arm descriptions
Study NCT02787239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Study NCT02787239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT02787239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Study NCT02787239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Study NCT00869778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: εPA-44
Description: subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
Study NCT00869778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
Study NCT00869778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
Study NCT00411580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106
Study NCT00411580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03997045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise program
Description: Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
Study NCT03196388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is >95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 573719 +GW642444 125/25
Description: 125mcg/ 25mcg
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK 573719 +GW642444 125/25
Description: 125mcg/ 25mcg
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 + GW642444 62.5/25
Description: 62.5mcg/25mcg
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 + GW642444 62.5/25
Description: 62.5mcg/25mcg
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 573719 125
Description: 125mcg
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK 573719 125
Description: 125mcg
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 573719 62.5
Description: 62.5mcg
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK 573719 62.5
Description: 62.5mcg
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 25
Description: 25mcg
Study NCT01328444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plb
Description: Comparator